Headache for Zosano as FDA turns down migraine patch

Zosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking for new bioequivalence data.

FREE TO ATTEND | Inhalation & Respiratory Drug Delivery Even...

08 - 09 July 2020 | BST (UTC+1) | FREE TO ATTEND

FREE TO ATTEND | Formulation & Drug Delivery Event: Virtual

FREE TO ATTEND

J&J defends Darzalex with FDA approval for faster dosing

Takeda signs $882m rare disease alliance with Oxford biotech...

Registration opens for SMi’s 3rd annual Injectable Drug Deli...

Injectable Drug Delivery Conference returns to London